Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Characterization of MicroRNAs Regulating FOXO Expression.

Hanniford D, Hernando E.

Methods Mol Biol. 2019;1890:13-28. doi: 10.1007/978-1-4939-8900-3_2.

PMID:
30414141
2.

Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy.

Lattanzi M, Lee Y, Simpson D, Moran U, Darvishian F, Kim RH, Hernando E, Polsky D, Hanniford D, Shapiro R, Berman R, Pavlick AC, Wilson MA, Kirchhoff T, Weber JS, Zhong J, Osman I.

J Natl Cancer Inst. 2019 Feb 1;111(2):180-188. doi: 10.1093/jnci/djy086.

PMID:
29912415
3.

MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway.

Koetz-Ploch L, Hanniford D, Dolgalev I, Sokolova E, Zhong J, Díaz-Martínez M, Bernstein E, Darvishian F, Flaherty KT, Chapman PB, Tawbi H, Hernando E.

Pigment Cell Melanoma Res. 2017 May;30(3):328-338. doi: 10.1111/pcmr.12578. Epub 2017 Apr 19.

4.

A TGFβ-miR-182-BRCA1 axis controls the mammary differentiation hierarchy.

Martinez-Ruiz H, Illa-Bochaca I, Omene C, Hanniford D, Liu Q, Hernando E, Barcellos-Hoff MH.

Sci Signal. 2016 Dec 6;9(457):ra118.

5.

BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma.

Paoluzzi L, Hanniford D, Sokolova E, Osman I, Darvishian F, Wang J, Bradner JE, Hernando E.

Cancer Med. 2016 Jun;5(6):1183-93. doi: 10.1002/cam4.667. Epub 2016 May 11.

6.

SPROUTY-2 represses the epithelial phenotype of colon carcinoma cells via upregulation of ZEB1 mediated by ETS1 and miR-200/miR-150.

Barbáchano A, Fernández-Barral A, Pereira F, Segura MF, Ordóñez-Morán P, Carrillo-de Santa Pau E, González-Sancho JM, Hanniford D, Martínez N, Costales-Carrera A, Real FX, Pálmer HG, Rojas JM, Hernando E, Muñoz A.

Oncogene. 2016 Jun 9;35(23):2991-3003. doi: 10.1038/onc.2015.366. Epub 2015 Oct 12.

7.

Revisiting determinants of prognosis in cutaneous melanoma.

Weiss SA, Hanniford D, Hernando E, Osman I.

Cancer. 2015 Dec 1;121(23):4108-23. doi: 10.1002/cncr.29634. Epub 2015 Aug 26. Review.

8.

A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis.

Hanniford D, Zhong J, Koetz L, Gaziel-Sovran A, Lackaye DJ, Shang S, Pavlick A, Shapiro R, Berman R, Darvishian F, Shao Y, Osman I, Hernando E.

Clin Cancer Res. 2015 Nov 1;21(21):4903-12. doi: 10.1158/1078-0432.CCR-14-2566. Epub 2015 Jun 18.

9.

Identification of metastasis-suppressive microRNAs in primary melanoma.

Hanniford D, Segura MF, Zhong J, Philips E, Jirau-Serrano X, Darvishian F, Berman RS, Shapiro RL, Pavlick AC, Brown B, Osman I, Hernando E.

J Natl Cancer Inst. 2015 Feb 12;107(3). pii: dju494. doi: 10.1093/jnci/dju494. Print 2015 Mar.

10.

Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients.

Fleming NH, Zhong J, da Silva IP, Vega-Saenz de Miera E, Brady B, Han SW, Hanniford D, Wang J, Shapiro RL, Hernando E, Osman I.

Cancer. 2015 Jan 1;121(1):51-9. doi: 10.1002/cncr.28981. Epub 2014 Aug 25.

11.

BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy.

Segura MF, Fontanals-Cirera B, Gaziel-Sovran A, Guijarro MV, Hanniford D, Zhang G, González-Gomez P, Morante M, Jubierre L, Zhang W, Darvishian F, Ohlmeyer M, Osman I, Zhou MM, Hernando E.

Cancer Res. 2013 Oct 15;73(20):6264-76. doi: 10.1158/0008-5472.CAN-13-0122-T. Epub 2013 Aug 15.

12.

MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy.

Segura MF, Greenwald HS, Hanniford D, Osman I, Hernando E.

Carcinogenesis. 2012 Oct;33(10):1823-32. doi: 10.1093/carcin/bgs205. Epub 2012 Jun 12. Review.

13.

Histology-specific microRNA alterations in melanoma.

Poliseno L, Haimovic A, Segura MF, Hanniford D, Christos PJ, Darvishian F, Wang J, Shapiro RL, Pavlick AC, Berman RS, Hernando E, Zavadil J, Osman I.

J Invest Dermatol. 2012 Jul;132(7):1860-8. doi: 10.1038/jid.2011.451. Epub 2012 May 3.

14.

miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis.

Gaziel-Sovran A, Segura MF, Di Micco R, Collins MK, Hanniford D, Vega-Saenz de Miera E, Rakus JF, Dankert JF, Shang S, Kerbel RS, Bhardwaj N, Shao Y, Darvishian F, Zavadil J, Erlebacher A, Mahal LK, Osman I, Hernando E.

Cancer Cell. 2011 Jul 12;20(1):104-18. doi: 10.1016/j.ccr.2011.05.027.

15.

Clinical relevance of SKP2 alterations in metastatic melanoma.

Rose AE, Wang G, Hanniford D, Monni S, Tu T, Shapiro RL, Berman RS, Pavlick AC, Pagano M, Darvishian F, Mazumdar M, Hernando E, Osman I.

Pigment Cell Melanoma Res. 2011 Feb;24(1):197-206. doi: 10.1111/j.1755-148X.2010.00784.x. Epub 2010 Oct 21.

16.

3-Indolyl sultams as selective CRTh2 antagonists.

Tumey LN, Robarge MJ, Gleason E, Song J, Murphy SM, Ekema G, Doucette C, Hanniford D, Palmer M, Pawlowski G, Danzig J, Loftus M, Hunady K, Sherf B, Mays RW, Stricker-Krongrad A, Brunden KR, Bennani YL, Harrington JJ.

Bioorg Med Chem Lett. 2010 Jun 1;20(11):3287-90. doi: 10.1016/j.bmcl.2010.04.046. Epub 2010 Apr 14.

PMID:
20457519
17.

Melanoma MicroRNA signature predicts post-recurrence survival.

Segura MF, Belitskaya-Lévy I, Rose AE, Zakrzewski J, Gaziel A, Hanniford D, Darvishian F, Berman RS, Shapiro RL, Pavlick AC, Osman I, Hernando E.

Clin Cancer Res. 2010 Mar 1;16(5):1577-86. doi: 10.1158/1078-0432.CCR-09-2721. Epub 2010 Feb 23.

18.

Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor.

Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, Alvarez-Diaz S, Zakrzewski J, Blochin E, Rose A, Bogunovic D, Polsky D, Wei J, Lee P, Belitskaya-Levy I, Bhardwaj N, Osman I, Hernando E.

Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1814-9. doi: 10.1073/pnas.0808263106. Epub 2009 Feb 2.

19.

Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes.

Song J, Hanniford D, Doucette C, Graham E, Poole MF, Ting A, Sherf B, Harrington J, Brunden K, Stricker-Krongrad A.

Assay Drug Dev Technol. 2005 Dec;3(6):649-59.

PMID:
16438660
20.

Generation of cell lines for drug discovery through random activation of gene expression: application to the human histamine H3 receptor.

Song J, Doucette C, Hanniford D, Hunady K, Wang N, Sherf B, Harrington JJ, Brunden KR, Stricker-Krongrad A.

Assay Drug Dev Technol. 2005 Jun;3(3):309-18.

PMID:
15971992
21.

Isosteric ramatroban analogs: selective and potent CRTH-2 antagonists.

Robarge MJ, Bom DC, Tumey LN, Varga N, Gleason E, Silver D, Song J, Murphy SM, Ekema G, Doucette C, Hanniford D, Palmer M, Pawlowski G, Danzig J, Loftus M, Hunady K, Sherf BA, Mays RW, Stricker-Krongrad A, Brunden KR, Harrington JJ, Bennani YL.

Bioorg Med Chem Lett. 2005 Mar 15;15(6):1749-53.

PMID:
15745833

Supplemental Content

Loading ...
Support Center